查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1524249

原代细胞培养市场 - 按细胞类型、组成、应用、最终用户 - 全球预测

Primary Cell Culture Market - By Cell Type, Component, Application, End-user - Global Forecast
出版日期: | 出版商: Global Market Insights Inc. | 英文 190 Pages | 商品交期: 2-3个工作天内

价格
简介目录

随着人们对再生医学的兴趣日益浓厚，全球原代细胞培养市场在 2024 年至 2032 年间的复合年增长率将超过 12.2%。由于再生医学旨在使用细胞疗法修復或替换受损的组织和器官，因此对原代细胞培养物作为真实细胞模型的需求激增。这些培养物使研究人员能够研究对于开发有效的再生疗法至关重要的细胞行为、分化和相互作用。这一趋势强调了原代细胞培养在推进利用人体修復机制的治疗、在解决慢性疾病方面有望取得突破以及透过个人化医疗干预改善患者预后的关键作用。

举个例子，2023年10月，加州再生医学研究所向南加州大学凯克医学院捐赠了200万美元。这笔资金鼓励他们建立新的 cGMP 实验室，该实验室旨在加速细胞和基因疗法的早期研究，透过现代技术整合将实验室发现与临床应用联繫起来。

整个原代细胞培养产业根据细胞类型、成分、应用、最终用户和地区进行细分。

到2032 年，人类细胞领域将占据大量原代细胞培养市场份额。 。与细胞系相比，原代人类细胞可以更准确地代表人类生物学，这使得它们对于研究疾病机制和测试新疗法不可或缺。这种精确度对于药物发现和开发至关重要，研究人员越来越依赖原代细胞来验证药物功效和安全性。此外，细胞培养技术的进步，加上生物製药研究投资的不断增加，进一步推动了原代细胞培养在应对复杂的医疗保健挑战方面的采用。

由于其在生物製药生产和研究中的关键作用，到 2032 年，培养基领域将在原代细胞培养市场中实现可观的复合年增长率。原代细胞培养对于生产疫苗、单株抗体和其他生物製剂至关重要，可促进生物製药产业的成长。这些文化为扩大生产规模提供了可靠的平台，同时保持产品的一致性和品质。此外，细胞培养基配方和生物加工技术的进步提高了原代细胞生物製药的效率和产量。这种不断增长的需求凸显了它们在满足全球医疗保健需求和推动治疗创新方面的至关重要性。

北美原代细胞培养市场从 2024 年到 2032 年将呈现显着的复合年增长率。此外，严格的监管标准和对品质控制的高度重视推动了原代细胞培养物用于药物测试和验证目的。此外，北美先进的医疗基础设施以及学术界、研究机构和製药公司之间的重要合作为推进细胞培养技术创造了有利的环境。这些因素共同促进了北美在蓬勃发展的市场扩张中的领先地位。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 原代细胞培养产品在体外测试中的使用不断增加
      • 癌症和其他持续性健康状况的盛行率不断上升
      • 基因工程方案不断进步
      • 增加对功能生物学和研究的资助
    • 产业陷阱与挑战
      • 与使用原代细胞相关的伦理和监管问题
      • 与原代细胞相关的限制
  • 成长潜力分析
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略展望矩阵

第 5 章：市场估计与预测：按电池类型，2021 - 2032 年

  • 主要趋势
  • 动物细胞
  • 人体细胞

第 6 章：市场估计与预测：按组成部分，2021 - 2032 年

  • 主要趋势
  • 产品
    • 血球
    • 神经细胞
    • 骨髓
    • 内皮细胞
    • 皮肤细胞
    • 肌肉细胞
    • 其他细胞类型
  • 媒体
  • 试剂和补充剂
    • 细胞解离和细胞附着解决方案
    • 缓衝液和盐
    • 细胞冷冻介质
    • 血清、生长因子和细胞因子
    • 其他试剂和补充剂

第 7 章：市场估计与预测：按应用分类，2021 - 2032

  • 主要趋势
  • 药物筛选和毒性测试
  • 疫苗生产
  • 细胞和基因疗法开发
  • 再生医学
  • 其他应用

第 8 章：市场估计与预测：按最终用户划分，2021 - 2032 年

  • 主要趋势
  • 製药和生物技术公司
  • 研究机构和学术实验室
  • 合约研究组织 (CRO)
  • 其他最终用户

第 9 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿联酋
    • 中东和非洲其他地区

第 10 章：公司简介

  • BioLamina AB
  • Corning Incorporated
  • Creative Bioarray
  • Cyagen
  • FUJIFILM Wako Pure Chemical Corporation
  • Kosheeka
  • Lifeline Cell Technology,
  • Lonza Bioscience
  • Merck KGaA
  • PELOBIOTECH GmbH
  • PromoCell GmbH
  • STEMCELL Technologies
  • Thermo Fisher Scientific Inc.
简介目录
Product Code: 9208

Global Primary Cell Culture Market will demonstrate over 12.2% CAGR between 2024 and 2032, ushered by the rising interest in regenerative medicine. As regenerative medicine aims to repair or replace damaged tissues and organs using cellular therapies, the demand for primary cell cultures as authentic cellular models has surged. These cultures enable researchers to study cell behavior, differentiation, and interactions crucial for developing effective regenerative therapies. This trend underscores the pivotal role of primary cell cultures in advancing treatments that harness the body's repair mechanisms, promising breakthroughs in addressing chronic diseases, and improving patient outcomes through personalized medical interventions.

Quoting an instance, in October 2023, Californias Institute of Regenerative Medicine awarded USD 2 million to USCs Keck School of Medicine. The funding encourages their new cGMP Laboratory, designed to accelerate early-stage research on cell and gene therapies, bridging lab discoveries to clinical applications with modern technology integration.

The overall primary cell culture industry is segmented based on cell type, component, application, end-user, and region.

The human cells segment will capture a substantial primary cell culture market share by 2032. The demand for primary cell culture across the human cells segment is rising due to its critical role in advancing personalized medicine and regenerative therapies. Primary human cells offer a more accurate representation of human biology compared to cell lines, making them indispensable for studying disease mechanisms and testing novel therapeutics. This precision is essential in drug discovery and development, where researchers increasingly rely on primary cells to validate drug efficacy and safety profiles. Moreover, advancements in cell culture techniques, coupled with growing investments in biopharmaceutical research, further drive the adoption of primary cell cultures in addressing complex healthcare challenges.

The media segment will register a considerable CAGR in the primary cell culture market through 2032, owing to its pivotal role in biopharmaceutical production and research. Primary cell cultures are essential for producing vaccines, monoclonal antibodies, and other biologics, boosting growth in the biopharmaceutical industry. These cultures provide a reliable platform for scaling up production while maintaining product consistency and quality. Moreover, advancements in cell culture media formulations and bioprocessing technologies enhance the efficiency and yield of biopharmaceuticals derived from primary cells. This growing demand underscores their critical importance in meeting global healthcare needs and advancing therapeutic innovations.

North America primary cell culture market will exhibit a significant CAGR from 2024 to 2032. One key driver is the regions strong presence in biopharmaceutical research and development, supported by substantial investments in healthcare innovation. Additionally, stringent regulatory standards and a high emphasis on quality control propel the adoption of primary cell cultures for drug testing and validation purposes. Moreover, North America advanced healthcare infrastructure and significant collaborations between academia, research institutes, and pharmaceutical companies foster a conducive environment for advancing cell culture technologies. These factors collectively contribute to North America leadership in thriving market expansion.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising usage of primary cell culture products in in-vitro testing
      • 3.2.1.2 Increasing prevalence of cancer and other persistent health conditions
      • 3.2.1.3 Growing advancement in genetic engineering protocols
      • 3.2.1.4 Increase in funding for functional biology and research
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Ethical and regulatory concerns related to the use of primary cells
      • 3.2.2.2 Limitations associated with primary cells
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Cell Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Animal cells
  • 5.3 Human cells

Chapter 6 Market Estimates and Forecast, By Component, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Products
    • 6.2.1 Blood cell
    • 6.2.2 Nerve cell
    • 6.2.3 Bone marrow
    • 6.2.4 Endothelial cell
    • 6.2.5 Skin cell
    • 6.2.6 Muscle cell
    • 6.2.7 Other cell types
  • 6.3 Media
  • 6.4 Reagents & supplements
    • 6.4.1 Cell dissociation and cell attachment solutions
    • 6.4.2 Buffers and salts
    • 6.4.3 Cell freezing media
    • 6.4.4 Sera, growth factors & cytokines
    • 6.4.5 Other reagents & supplements

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Drug screening and toxicity testing
  • 7.3 Vaccine production
  • 7.4 Cell & gene therapy development
  • 7.5 Regenerative medicine
  • 7.6 Other applications

Chapter 8 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Pharmaceutical and biotechnology companies
  • 8.3 Research institutes and academic laboratories
  • 8.4 Contract research organizations (CROs)
  • 8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 South Africa
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 BioLamina AB
  • 10.2 Corning Incorporated
  • 10.3 Creative Bioarray
  • 10.4 Cyagen
  • 10.5 FUJIFILM Wako Pure Chemical Corporation
  • 10.6 Kosheeka
  • 10.7 Lifeline Cell Technology,
  • 10.8 Lonza Bioscience
  • 10.9 Merck KGaA
  • 10.10 PELOBIOTECH GmbH
  • 10.11 PromoCell GmbH
  • 10.12 STEMCELL Technologies
  • 10.13 Thermo Fisher Scientific Inc.